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Advances in diagnostic research are moving towards methods whereby the periodontal risk can be identified and quantified by objective
measures using biomarkers. Patients with periodontitis may have elevated circulating levels of specific inflammatory markers that can
be correlated to the severity of the disease. The purpose of this study was to evaluate whether differences in the serum levels of
inflammatory biomarkers are differentially expressed in healthy and periodontitis patients. Twenty-five patients (8 healthy patients
and 17 chronic periodontitis patients) were enrolled in the study. A 15 mL blood sample was used for identification of the inflammatory
markers, with a human inflammatory flow cytometry multiplex assay. Among 24 assessed cytokines, only 3 (RANTES, MIG and
Eotaxin) were statistically different between groups (p<0.05). In conclusion, some of the selected markers of inflammation are
differentially expressed in healthy and periodontitis patients. Cytokine profile analysis may be further explored to distinguish the
periodontitis patients from the ones free of disease and also to be used as a measure of risk. The present data, however, are limited and
larger sample size studies are required to validate the findings of the specific biomarkers.
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INTRODUCTION
Periodontitis is a group of inflammatory diseases
that affect the connective tissue attachment and sup-
porting bone around the teeth. It results from interac-
tions between periodontal microflora and the multifac-
eted response of the host. Initiation and progression of
periodontitis are dependent on the presence of virulent
microorganisms capable of causing disease. Although
bacteria are initiating agents in periodontitis, host re-
sponse to the pathogenic infection is critical to disease
progression (1).
Over the last 50 years, the prevailing view among
dentists and physicians has been that periodontal infec-
tions are localized only to the marginal periodontium and
that, as such, they rarely have systemic implications in
healthy individuals. More recent evidence, however, has
indicated that periodontitis patients present increased
systemic inflammation, as indicated by elevated serum
levels of various inflammatory markers when compared
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to those in unaffected control populations (2).
The diagnosis of active phases of periodontal
disease and the identification of patients at risk for active
disease represent a challenge for both clinical investiga-
tors and clinicians. Advances in oral and periodontal
disease diagnostic research are moving towards meth-
ods whereby periodontal risk can be identified and
quantified by objective measures, such as biomarkers.
These biomarkers of host response can be found in
gingival crevicular fluid, saliva and serum samples and
can potentially be used as diagnostic markers (3).
It has been proposed that patients with periodon-
titis may have elevated circulating levels of some inflam-
matory markers. Monocytes, macrophages and other
cells (including fibroblasts and endothelial cells) re-
spond to the dental plaque microorganisms, membrane-
associated vesicles, lipopolysaccharides (LPS), and
other soluble and particular fractions by secreting a
number of chemokines and inflammatory cytokines,
especially tumor necrosis factor (TNF)-α, prostaglan-
din (PGE2), interleukins (IL-1β and IL-6). These in-
flammatory cytokines and prostaglandin have been
associated with the presence of various bacterial infec-
tions including periodontitis (4).
Elevated levels of IL-6 in blood or biological
fluids have been reported in association with immuno-
pathologies, such as in tissue injury, infection and some
inflammatory diseases (5). Many studies have shown
dramatic elevation of IL-6 levels in inflammatory peri-
odontal lesions and IL-6 is also thought to be a useful
indicator or a diagnostic marker for periodontitis (6-8).
The elevation in cytokines expression by cells within the
gingival connective tissue in chronic periodontitis le-
sions can theoretically spill over into the circulation
where it can induce or perpetuate systemic effects (9).
Although several studies (7,8,13-15) has dem-
onstrated that the biological activity of a variety of
cytokines may be directly relevant to periodontal de-
struction, such as periodontal attachment loss, destruc-
tion of collagen and alveolar bone resorption. Biologic
mechanisms for the progression of periodontitis are not
fully understood and, though much attention has been
focused on this subject, still remain controversial. The
individual course of periodontal diseases and the vari-
ability of clinical parameters, which may lead to tooth
loss in the absence of early and appropriate treatment,
led us to undertake a complex study on the key cytokines
responsible for the initiation, progression and/or sup-
pression of inflammatory response (10). Thus, consid-
ering the evidences and need to further investigate the
advances in oral and periodontal disease diagnostic
research, the purpose of this study was to evaluate the
differences in the serum levels of inflammatory biomarkers
in healthy and periodontitis patients. 
MATERIAL AND METHODS
Study Population
This clinical study was conducted as a joint
collaboration of the Department of Oral and Maxillofa-
cial Surgery and Traumatology and Periodontics, School
of Dentistry of Ribeirão Preto, and the Department of
Clinical Analysis, School of Pharmaceutics Sciences of
Ribeirão Preto, University of São Paulo.
Patients that fulfilled the entry clinical criteria for
the inclusion in the study were examined by a single
experienced examiner and, according to their periodon-
tal condition and general health status, they were either
invited or not to participate in the study.   
Inclusion criteria were: (i) healthy patients; (ii) at
least one site with probing depth ≥5 mm and two teeth
with attachment loss ≥6 mm (11). Exclusion criteria
were: (i) use of antibiotics or periodontal treatment in the
previous 6 months; (ii) smoking within the past 5 years;
(iii) pregnancy or lactancy; (iv) concomitant medical
therapy. The study was independently reviewed and
approved by the Institutional Human Research Commit-
tee. The patients who qualified for the study were
rescheduled for laboratory, periodontal, radiographic
and clinical examinations. From the initial screening, 25
patients (8 healthy individuals  + 17 chronic periodontitis
patients) met all inclusion criteria, did not meet any
exclusion criteria, and agreed to participate in the study.
   
Clinical Data Collection
The periodontal measurements were performed
by a single experienced examiner and recorded at 6 sites
per tooth using a computerized periodontal probe (Florida
Probe®; Florida Probe Corporation, Gainesville, FL,
USA). The parameters recorded were as follows: prob-
ing pocket depth (PPD), clinical attachment level (CAL),
bleeding on probing (BOP), number of teeth (N. teeth),
probing pocket depth ≥7mm (PPD ≥7 mm) and probing
pocket depth between 4 mm and 6 mm (PPD 4-6 mm).
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Inflammatory Markers and Sample Collection    
A 15 mL blood sample was obtained by veni-
puncture from each participant. Serum was collected by
centrifugation, aliquoted, stored and processed at the
end of the study by blinded staff.
The inflammatory markers were simultaneously
identified using human inflammatory flow cytometry
multiplex assays (BD™ Cytometric Bead Array - CBA;
BD Bioscience, San Jose, CA, USA). CBA, commonly
referred to as a multiplexed bead assay, is a series of
spectrally discrete particles that can be used to capture
soluble analytes. The analytes are then measured by
detection of a fluorescence-based emission and flow
cytometric analysis. The method employs a series of
different particles that are stably labeled with a fluores-
cent dye whose emission wavelength is read at ~ 650
nm. Each different group of beads is labeled with a
discrete level of fluorescent dye so that it can be
distinguished by its mean fluorescent intensity. The
beads within each group are covalently coupled with
antibodies that can specifically capture a particular type
of molecule present within biological fluids.    
The multiplex assay was chosen because it al-
lows a more complete analysis of biomarkers involved
in periodontitis and systemic diseases.     
Statistical Analysis
Mean CAL, PPD, BOP, N. teeth and serum
biomarkers were calculated for each subject and group,
and were compared between the two groups using a
two-sample Mann-Whitney U test. Data were tested for
normality before applying the adequate non-parametric
tests. Correlation between serum biomarkers and clini-
cal parameters was verified by computing Pearson’s
Correlation Coefficient. Statistical significance was con-
sidered for p-value <0.05.
RESULTS
Clinical Parameters
The periodontal measurements and levels of
inflammatory mediators were measured in serum
samples of 17 patients with chronic periodontitis (test
group), as well as 8 healthy subjects (control group).
The periodontal measurements of participants
recruited for this study are summarized in Table 1. For
the Mann-Whitney test, data showed that the periodon-
tal parameters evaluated (PPD, PPD 4-6 mm, PPD ≥7
mm, CAL, BOP and N. teeth), when compared between
groups (control and test) was statistically significant (p
≤0.001). The control group showed no signs of inflam-
mation (e.g.: BOP) or periodontal pockets, whereas in
test group, inflammation and periodontal pockets were
always present. In addition, the test group showed
periodontitis regarding its type (chronic periodontitis)
and severity (moderate to severe probing depth ≥6mm).
However, in most subjects, moderate to severe peri-
odontitis was localized on some teeth.
Immunological Parameters
Table 2 shows the levels of serum mediators in
both groups. The inflammatory mediators IL-9, RANTES,
Human GM-CSF, MIP-1β and INF-γ were reduced in
test patients compared to control patients, but only
RANTES levels were statistically significant (p = 0.016).
IL-1β, MIG, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-
12p70, IP-10, Human B FGF, Human Fas Ligand, Human
G-CSF, Human LT-α, Human MCP-1, MIP-1α, Human
TGF-β, G-CSF, Eotaxin and TNF-α levels were in-
creased when test and control groups were compared,
but only MIG and Eotaxin levels were statistically signifi-
cantly (p = 0.033 and p = 0.0124 respectively).   
Levels of Serum Mediators Correlated with Clinical
Parameters
The correlation between serum mediators and
clinical parameters was analyzed for Eotaxin, RANTES
Table 1. Periodontal measurements of patients.
Clinical parameters Control group Test group p value
PPD 1.75 ± 0.27 3.22 ± 1.08 p < 0.001
PPD 4-6 mm 0.00 13.71 ± 9.05 p < 0.001
PPD ≥7 mm 0.00 4.53 ± 5.36 p = 0.001
CAL 1.73 ± 0.29 3.76 ± 1.11 p < 0.001
BOP 0.00 0.48 ± 0.24 p < 0.001
N. teeth 29.71 ± 2.14 21.72 ± 4.44 p < 0.001
PPD= probing pocket depth; CAL= clinical attachment level;
BOP= bleeding on probing; N. teeth= number of teeth.
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and MIG, which showed statistical significance.
RANTES showed higher levels in the control group than
in the test group, though when correlated with all clinical
parameters, it presented lower levels of correlation
without statistical significance (Table 3). In the test
group, there were higher levels of Eotaxin and MIG.
Eotaxin did not show statistically significant correlation
with any clinical parameter. Elevated MIG levels were
correlated only with N. teeth. However, in this case, the
correlation was not statistically significant (Table 4).
DISCUSSION
Cytokines are small polypeptides with a wide
spectrum of inflammatory, hemopoietic, metabolic and
immunomodulatory properties. They are produced by a
variety of cells, including the macrophage/monocyte
Table 2. Serum mediators (pg/mL) of control and test groups.
Mediator Control group Test group p value
IL-2 7.8 ± 15.1 13.0 ± 25.2 0.2953 ↑
IL-4 2.1 ± 3.5 4.7 ± 9.4 0.2375 ↑
IL-5 2.3 ± 0.7 2.5 ± 4.7 0.4460 ↑
IL-6 0.8 ± 0.9 2.0 ± 3.4 0.1755 ↑
IL-7 3.0 ± 3.7 6.0 ± 14.6 0.2879 ↑
IL-8 7.0 ± 3.1 10.0 ± 12.7 0.2541 ↑
IL-1β 0.4 ± 1.1 5.9 ± 15.2 0.1586 ↑
IP-10 65.7 ± 49.8 81.1 ± 43.7 0.2199 ↑
IL-9 22.9 ± 64.9 1.0 ± 3.1 0.0837 ↓
IL-10 0.6 ± 0.8 3.0 ± 8.5 0.2132 ↑
MIP-1α 4.7 ± 4.1 10.5 ± 17.5 0.1838 ↑
Human B FGF 14.1 ± 39.9 34.8 ± 128.2 0.3313 ↑
Human Fas Ligand 22.3 ± 11.1 24.7 ± 35.2 0.4273 ↑
Eotaxin 35.8 ± 16.5 74.8 ± 44.2 0.0124* ↑
Human G-CSF 6.2 ± 4.0 11.7 ± 15.8 0.1734 ↑
Human GM-CSF 1.3 ± 2.3 0.7 ± 2.3 0.2668 ↓
RANTES 20958.5 ± 18356.9 ± 0.0075* ↓
2201.2 2356.0
Human LT-α 0.4 ± 1.1 5.3 ± 13.9 0.1652 ↑
Human MCP-1 77.1 ± 44.7 126.9 ± 124.0 0.1429 ↑
Human TNF 0.9 ± 1.8 6.4 ± 17.3 0.1949 ↑
MIP-1β 942.9 ± 174.2 ± 0.1037 ↓
2482.5 226.5
IL-12 p70 2.9 ± 1.7 8.7 ± 23.7 0.2479 ↑
INF-γ 28.0 ± 68.4 17.0 ± 28.0 0.2849 ↓
MIG 86.8 ± 34.0 194.1 ± 186.1 0.033651* ↑
* = significant difference (p<0.05); Values are shown as mean ± SD.
Table 3. Correlations between clinical parameters and levels of
serum mediators in the control patients.
Clinical RANTES
Parameters
Correlation p value
CAL 0.130 0.759
PPD 0.176 0.678
PPD 4-6 mm Not tested* -
PPD ≥7 mm Not tested* -
BOP Not tested* -
N. teeth 0.146 0.730
*Variables not tested due to absence of clinical measurements.
PPD= probing pocket depth; CAL= clinical attachment level;
BOP= bleeding on probing; N. teeth = number of teeth.
Table 4. Correlations between clinical parameters and levels of
serum mediators in the test group.
Clinical Eotaxin MIG
Parameters
Correlation p value Correlation p value
CAL 0.014 0.957 -0.25 0.925
PPD 0.037 0.887 -0.177 0.496
PPD 4-6 mm 0.015 0.954 0.038 0.885
PPD ≥7 mm 0.284 0.269 -0.096 0.713
BOP 0.246 0.341 -0.123 0.638
N. teeth 0.139 0.596 0.596 0.596
PPD= probing pocket depth; CAL= clinical attachment level;
BOP= bleeding on probing; N. teeth = number of teeth.
system, dendritic cells, lymphocytes, neutrophils, en-
dothelial cells and fibroblasts. As a consequence,
cytokines and their receptors form a network of high
complexity that is under tight but complex biological
control, including positive and negative feedback by the
cytokines themselves. It is well known that immunity
depends on two major types of specific immune re-
sponses, the cellular and humoral responses. The bal-
ance between them is strongly regulated by factors
associated with antigen-presenting cells (APC) and by
cytokines produced by T helper (Th) cells (12).
Several studies (7,8,13-15) have demonstrated
that some cytokines, such as interleukin-12 (IL-12),
interleukin-1 beta (IL-1β), interferon gama (IFN-γ),
interleukin-6 (IL-6) and tumor necrosis factor alpha
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(TNF-α), are involved in Th1 immune responses and
induce mainly cell-mediated immunity. In contrast,
interleukin-4 (IL-4), interleukin-5 (IL-5) and interleukin-
10 (IL-10) are involved in Th2 immune responses and
promote humoral immunity due to the production of B
cell growth and differentiation factors (13). Cytokines
produced by Th1 and Th2 cells are mutually inhibitory
for the differentiation and effector functions of the
reciprocal phenotype. Thus, IFN-γ selectively inhibits
the proliferation of Th2 cells, while IL-4 and IL-10
inhibit cytokine synthesis by Th1 cells. Moreover, IL-
4 suppresses the synthesis of proinflammatory cytokines,
including IL-1 and TNF-α, which induce several events
associated with inflammation, tissue destruction, bone
resorption and production of matrix metalloproteinases
and prostaglandin E2 (14). One of the major sources of
IL-1β and TNF-α in inflamed tissues are tissue mono-
cytes/macrophages. IFN-γ and IL-2 are produced mainly
by Th1 cells, while IL-4 and IL-10 by the Th2 subset. All
these cytokines play a key role in immune and inflamma-
tory responses, and infection outcome may be attribut-
able to the balance in the relative rate among all of them.
    Górska et al. (15) assessed the relationship between
clinical parameters and concentrations of the key
cytokines (IL-1β, TNF-α, IL-2, IFN-γ, IL-4, IL-10),
important in the initiation and progression of periodontal
disease, within inflamed gingival tissues and serum
samples from patients with severe chronic periodonti-
tis. The concentrations of IL-1β, TNF-α, IL-2, IFN-γ
were, on average, significantly higher in serum samples
and gingival tissue biopsies from periodontitis patients
than in healthy controls. However, serum samples from
both groups showed high individual variability of cytokine
profiles, and no association between cytokine concen-
trations and clinical parameters of periodontitis was
found. On the contrary, IL-4 and IL-10 levels in both
kinds of samples obtained from patients and controls
were generally low or even undetectable, and remained,
on average, on the same level. These results indicate that
high variability of cytokine concentrations and low
frequency of their detection in serum samples from
periodontitis patients make these determinations useless
for the detection of disease presence and/or its severity.
RANTES (regulated upon activation, normal T
cell expressed and secreted) is a CC chemokine, which
preferentially has chemoattractant properties for mono-
cytes and memory T cells (16). It is a pro-inflammatory
chemokine and is found in sites of seveal inflammatory
disorders. It is also intimately linked to the function of
cytotoxic T lymphocytes, which are important in the
control of a number of intracellular pathogens. It has
been reported that chemokines, including RANTES,
mediate and stimulate the release of inflammatory prod-
ucts. However, the relative contribution of these
chemokine to the inflammatory diseases is still uncertain
(17). In this study, RANTES expressed higher serum
levels in the control group than in the test group. The
patients answered to a strict questionnaire. However, a
systemic inflammatory process could have been hidden
and, as RANTES is a multipotent mediator of inflamma-
tion, the data could have been altered.
MIG (monokine induced by interferon-γ), a
member of CXC chemokine superfamily, is up-regu-
lated by RANKL in osteoclast precursor cells. This
secreted low molecular weight protein has been impli-
cated in the directed migration, adhesion and activation
of macrophages, T cells, and B cells that express
CXCR3, the receptor for MIG. Furthermore, the ex-
pression of MIG induced by RANKL can stimulate the
adhesion and migration of M-CSF-dependent osteoclast
precursors and differentiating osteoclasts (18). In the
present study, it was observed that MIG presented
higher levels in the test group, which showed worse
clinical parameters (PPD, CAL). This result is accor-
dance with the literature, since the bone resorption is an
important event of destructive periodontal disease.
Eotaxin is a member of CC-chemokine family
with preferential chemotactic capacity for eosinophils.
Increased levels of eotaxin have been detected in the
serum/plasma of subjects with asthma and allergic
rhinitis, suggesting an important role in allergic diseases
(19). In the present study, higher levels of Eotaxin were
observed in test group. However, the literature does not
show a  relationship between periodontal disease and
Eotaxin. Unlike other chemokines, Eotaxin binds to only
one receptor, CCR3, which is highly expressed on eosi-
nophils. It has no activity on neutrophils and monocytes,
which do not seem to express CCR3. However, it does
show certain degree of chemotactic activity towards Th2
cells and basophils. These cells have also been shown to
express CCR3. This may explain why eotaxin has the
potential to mediate the migration of these cells and their
relationship with inflammatory process (20).
In conclusion, the systemic levels of the inflam-
matory mediators analyzed in this study presented a
similar profile in healthy and periodontitis patients.
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Although some cytokines have shown significant dif-
ferences between the groups, there are no compelling
data at this point to indicate that they can be used as
biomarkers for periodontal disease. Cytokine profile
analysis should be further explored to distinguish the
patients with periodontitis from those free of disease,
and also to be used as a measure of risk.
RESUMO
Avanços no diagnóstico da doença periodontal levam a métodos
nos quais o risco e atividade da doença periodontal podem ser
identificados e quantificados por biomarcadores. Pacientes com
periodontite podem apresentar elevados níveis circulatórios de
marcadores inflamatórios específicos que podem ser correlacionados
com a severidade da doença. Portanto, o objetivo desse estudo foi
avaliar as diferenças nos níveis séricos de biomarcadores inflamatórios
em pacientes saudáveis e com doença periodontal. Foram incluídos
no estudo 25 pacientes (8 saudáveis e 17 com periodontite crônica).
Uma amostra de 15 mL de sangue foi obtida para identificar os
marcadores inflamatórios simultaneamente utilizando Array de
proteínas através de citometria de fluxo. De 24 citocinas inflamatórias
analisadas, apenas 3 (RANTES, MIG e Eotaxina) apresentaram
diferenças estatisticamente significantes (p<0,05) entre os dois
grupos. Conclui-se que alguns marcadores inflamatórios selecionados
apresentam diferença de concentração em pacientes com
periodontite e saudáveis. A análise do perfil de citocinas pode ser
utilizada tanto para distinguir pacientes periodontais de pacientes
saudáveis, como para medir o risco à doença. Contudo, mais
estudos com número maior de amostras são necessários para validar
os achados sobre os biomarcadores específicos.
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